Ceva expands oral rabies vaccine portfolio with the acquisition of Canadian firm Artemis Technologies, Inc. >
This strategic acquisition complements Ceva’s rabies portfolio.
Ceva Santé Animale announces Japan-based joint venture with Mitsui >
Promoting Ceva Santé Animale’s image and business strategy in Japan
Ceva celebrates 100 years of developing animal vaccines at its Dessau site in Germany >
A century of significant contributions to animal health
Annual WVA Global Animal Welfare Awards held during the 37th World Veterinary Association Congress >
The WVA and Ceva Santé Animale are thrilled to continue their collaborations to underline and recognise the work done by outstanding people and institutions to advance animal welfare.
Ceva launched sow vaccine against Neonatal Diarrhoea with 7 antigens inside >
Broad coverage by a vaccine is important for pig producers to save time and effort and contribute to animal welfare.
Statement on the situation in Ukraine >
Our top priority is to protect our employees and their families and help farmers to cope with this dramatic situation.
Ceva’s vaccine against pandemic swine Flu, RESPIPORC Flupan H1N1, given extra claim for sows >
The extension of the claim to sows and gilts offers producers a significant economic benefit to further vaccination against flu strains.
Ceva partners with Liryc, the global leading institute in heart rhythm disorders >
The objective: to promote One Health platform of excellence dedicated to cardiology, stimulating research and medical innovation at the interface between humans and companion animals.
Ceva invests in its European vaccine production capacity to create the EU’s largest cryogenic storage facility in Monor >
The new site is situated in Monor, 40kms from the centre of Budapest.
Ceva’s QTest validated as an effective and practical way to diagnose Q fever in dairy herds worldwide >
This tool offers a breakthrough innovation to farmers and veterinarians, by making the diagnosis easier.